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INTRODUCTION
Cardiotoxicity remains a major concern during drug
development, with increased proarrhythmic potential being
the main culprit. The pharmaceutical industry is challenged
by the growing cost of research and development and cannot
afford drug attrition in late phases of development or
withdrawals of approved drugs. The ICH S7B non-clinical
and E14-based clinical methodologies have been successful in
their intent to reduce and eliminate drug-mediated torsades
de pointes (TdP) arrhythmias as there have not been any
withdrawals of marketed drugs for torsadogenic reasons since
these guidelines were adopted (1). However, the current
approach is conservative and can result in false positives.
Thus, while effective, the current paradigm may be inappro-
priately assigning TdP liability to some drugs, especially in the
discovery realm, so work is ongoing to shift from one that
strongly relies on QT interval prolongation (or is “hERG-
centric”) to one where proarrhythmic risk would be primarily
assessed using non-clinical in vitro human models based on
solid mechanistic considerations of TdP proarrhythmia (2) in
conjunction with the current in vivo QT conscious canine and
other non-rodent models.
Problems related to this drug-induced cardiotoxicity were
discussed at a symposium entitled “A Gentle Touch on the
Beating Heart: Early Discovery Prediction of Cardiotoxicity and
Its Covariates” and conducted during the AAPS 2014 Annual
Meeting. The aim of this mini-symposium was to present
methods of predicting cardiotoxicity (which will be defined
throughout this entire manuscript as a synonym of a
proarrhythmic effect) from early discovery data. Three speakers
from different backgrounds introduced the audience to the
current safety testing paradigm, the latest achievements within
drug safety and remaining hurdles regarding the integration of
multiple sources of data acquired both at the preclinical and
clinical level, and their translation to the human in vivo situation.
Despite a reasonable knowledge of the mechanisms related to
proarrhythmic cardiotoxicity, there are still questions whether
the new paradigm of testing will be able to provide all
stakeholders with a sufficient level of confidence with the
application of these novel concepts and models to drug safety.
This article gives a short overview of the discussed
problems, summarizes the discussion, and gives a flavor of a
new cardiac safety testing pathway likely to be introduced in
the near future. Some of the statements in the text, like the
feasibility of the individualized risk assessment, can be
contradictory what was left intentionally and shows the line
of discussion between speakers. The three leading topics
include a description of the molecular and clinical back-
ground of drug-induced proarrhythmic effects, a brief pre-
sentation of current methods used in the early prediction of
such effects together with anticipated changes in the testing
paradigm and a discussion of the in vitro–in vivo extrapola-
tion approach, all of which promise the possibility of risk
assessment at the individual patient level.
Molecular and Clinical Background of the Drug-Triggered
Cardiac Arrhythmia
The development of TdP is a potentially life-threatening
ventricular arrhythmia that can occur as an unintended result
of drug therapy of various, in many cases relatively benign,
conditions. It’s rare occurrence hinders TdP observation
considerably during the conduct of clinical trials, thus
necessitating the use of surrogate markers. For most medica-
tions known to cause torsades, TdP is a result of repolariza-
tion delay or alterations clinically reflected by QT interval
prolongation on the surface electrocardiogram (ECG).
Despite being considered an imperfect biomarker with
compromised sensitivity and specificity and lack of a straight-
forward correlation with TdP occurrence, QT interval pro-
longation remains the most globally used biomarker to assess
the proarrhythmic propensity of a drug (3,4). QT interval
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prolongation is a mechanism-based effect resulting primarily
from the inhibition of rapid delayed rectifier potassium
current (IKr) mediated by ion channels encoded by the
human ether-a-go-go-related gene (hERG or Kv11.1). It has
been shown that in vitro measured IKr inhibition potency
expressed as an IC50 value correlates with the clinically
observed arrhythmia occurrence (5,6). This fact is reflected in
the regulatory requirements, which require such in vitro study
to be conducted before a first-in-human trial (7). Despite the
importance of the hERG channel in safety pharmacology,
studies investigating hERG channel exclusively might not
fully reflect the drug potential in modifying cardiac ionic
currents. Since the action potential of ventricular
cardiomyocytes is a result of complex interplay between
inward and outward ionic currents, drug interaction with an
inward current can alter the effect of hERG inhibition of
outward current and hence may limit effects on the QT
interval and subsequent assessed proarrhythmic potential.
Indeed, there are potent hERG inhibitors devoid of TdP risk
(e.g., verapamil, propafenone, amiodarone, ranolazine) be-
cause of either a counteraction to potassium current inhibi-
tion by either sodium or calcium channel blockade or other
potential antiarrhythmic mechanisms (8,9). On the other
hand, alfuzosin is an example of a drug with negligible
hERG liability although it causes QTc interval prolongation
by increasing sodium current (8–11). Therefore, one of the
proposed changes to be implemented into cardiac safety
testing is an evaluation of the drug effects on multiple cardiac
ionic currents. Recently, Kramer et al. (12) assessed whether
determining concomitant block of multiple ion channels could
more accurately predict the torsadogenic potential of a
compound rather than just examining the effects on hERG
alone. The application of logistic regression models using data
derived from high-throughput screening multiple ion channel
electrophysiology (MICE) methods showed that for the
known 23 non-torsadogenic and 32 torsadogenic drugs from
multiple classes tested that there was a significant reduction in
false positives (i.e., type 1 errors) and false negatives (i.e.,
type 2 errors) when compared to assessment using the hERG
assay alone.
Currently, there are efforts to develop a Comprehensive
In vitro Proarrhythmia Assay (CIPA) that aims to modify and
modernize current non-clinical, “hERG-centric” cardiac safe-
ty screening efforts (2,13,14). Current alternative screening
models and methods under consideration for the CIPA
initiative include stem cells in which hERG (Kv11.1; IKr
current) as well as other cardiac ion channels such as the fast
sodium (Nav1.5; INa current) channel, persistent sodium
channel (INasus), calcium (Cav1.2; ICa current) channel as
well as potassium channels such as the inward rectifier
(Kir2.1-2.4; IK1 current), and slow delayed rectifying (Kv7.1;
IKs current) channel can be assessed in totality (15). Rather
than examining human ion channel isoforms heterogeneously
expressed in cell lines (such as CHO or HEK) as is current
practice in drug safety, there is ongoing investigation of the
applicability of human-induced pluripotent stem cells (16).
The undifferentiated human stem cell of embryonic origin
(hESC) and induced pluripotent stem cell (iPSCs) of somatic
origin continue to be evaluated for their cardiac electrophys-
iological potential for use as a drug screening assay (16–19).
Intracellular recordings from individual cells and multi-
electrode arrays (MEAs) enable measurement of sodium,
calcium, and potassium current from stem cells (16). Note,
however, that a limitation to the use of stem cells that are
currently being evaluated is that these cells are immature with
regard to their electrophysiological properties. Stem cells, to
date, do not appear to fully express all channels at the same
density and at the same proportion as occurs in human
ventricular myocytes (20).
Multi-channel interactions, hERG-independent
proarrhythmia mechanisms, active metabolites, or antiar-
rhythmic effects of a drug are not the only reasons for a lack
of absolute concordance of risk estimates based on surrogate
markers with actual TdP risk in a patient population. Apart
from pharmacodynamic effects, TdP occurrence is influenced
by many factors that define inter- and intra-individual
variability (21–23). It is known that TdP occurrence heavily
depends on concomitant risk factors including age, gender,
electrolyte imbalance, heart rate (specifically bradycardia),
and presence of structural heart disease. Also, the actual risk
for an individual patient is variable with individual circadian
rhythms (i.e., heart rate, serum electrolyte levels), and
rhythms with a longer periodicity (related to the effects of
sex hormones) can influence the individual response of the
heart to drugs (24,25). Mechanisms responsible for the
development of cardiac arrhythmias may be categorized
according to those that modify impulse formation (such as
altered normal automaticity or triggered activity caused by
early or delayed afterdepolarizations) or conduction (such as
that due to re-entry or re-excitation of cardiac tissue).
In humans, the most common causes of arrhythmias
include myocardial ischemia, myocardial infarction, or reper-
fusion of a previously ischemic myocardium. These conditions
can be readily reproduced in both intact and isolated hearts in
many species. While the pathogenesis of arrhythmias may not
appear to be relevant to drug safety, it is the mechanism(s)
derived from decades of arrhythmia studies that is being used
to define and explain drug-induced arrhythmogenesis. These
reported mechanisms may have direct implications in the
development of the CIPA paradigm and its ability to provide
additional information regarding the “proarrhythmia poten-
tial” for a new drug. The mechanism(s) that have been
developed will be important in the interpretation of ion
channel data and the predicted changes in the action potential
using suggested in silico models.
Abnormal impulse generation that may be responsible
for induction of TdP arrhythmias may arise from oscillations
in the membrane potential and has been characterized as a
“triggered” rhythm (26). These triggered rhythms occur in
two forms: early or late afterdepolarizations (EAD or DAD).
Early afterdepolarizations interrupt either phase 2 or 3
repolarization of the AP. If these afterdepolarizations attain
sufficient thresholds, they may produce triggered responses
and induce single or multiple extrasystoles or polymorphic
VT episodes such as TdP. The EAD is an oscillatory potential
that is sensitive to frequency and often occurs at slow
stimulation rates. EAD activity has been shown in vitro using
many types of isolated cardiac tissue and various cell types
including mid-myocardial cells (M-cell) (27). Induction of
EAD activity can be induced by a variety of drugs that block
sodium and potassium channels. When a transient depolari-
zation occurs during phase 4 of the cardiac AP, it is termed a
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delayed afterdepolarization (DAD) which is vitally depen-
dent upon the rate of the preceding action potential. Thus,
the amplitudes of DADs increase with decreasing cycle
lengths (28). DADs have been observed under a variety of
experimental conditions, all of which have a similar end
result—intracellular Ca2+ overload. High intracellular Ca2+
concentrations saturate sarcoplasmic reticulum sequestration
mechanisms resulting in Ca2+ oscillations due to Ca2+-induced
Ca2+ release (29). The ionic currents that contribute to this
mechanism are not known.
For many years, there has been an effort to mathemat-
ically describe the genesis of the cardiac action potential.
Primarily driven by academic research groups, there is now
ongoing integration of these in silico research methods to the
CIPA initiative. Of the many in silico models developed, it is
the O’Hara-Rudy model that will likely form the basis for the
in silico component of CIPA (30). The O’Hara model is a
human ventricular cardiac AP model based upon data
measured from over 100 undiseased human hearts.
Components of the model were evaluated over the human
range of physiological frequencies and include calcium versus
voltage-dependent inactivation of L-type calcium current
(ICaL); realistic kinetics for the transient outward, rapid
delayed rectifier (IKr), and inward rectifier (IK1) potassium
currents along with the Na+/Ca2+ exchanger (INaCa). The
authors also examined model response to rate dependence
and restitution of cardiac AP duration (APD).
Overview of Methods and Models Used in Assessment
of Drug-Induced Cardiotoxicity During Drug Development
The critical nature of cardiac liability determination and
implementation of an appropriate strategy for drug safety
assessment resulted in the development of three guidelines
that outlined non-clinical (ICH S7A; ICH S7B) and clinical
(ICH E14) testing strategies (7,31–33). The current non-
clinical testing strategy includes in vitro IKr current assess-
ment in heterologous mammalian cell lines expressing the
human ether-a-go-go-related gene (hERG, Kv11.1) channels,
which have been agreed to play a crucial role in human
cardiac electrophysiology. The preclinical guidelines propose
that sponsors consider other complementary models. These
include a number of in vitro assays that have been well
characterized with utility in the safety profiling of a new
chemical entity (NCE). These assays include assessment of
drug effects in the isolated rabbit Purkinje fiber preparation,
the isolated Langendorff heart, and the isolated wedge
preparation. Cardiac safety pharmacology in vivo methods
primarily use conscious telemetered animals to assess the
effects of the test item on the QT interval. Variables that are
usually recorded in the dog and other non-rodent species
include heart rate and the ECG. Thus, a variety of tests are
used to evaluate drug safety and include effects primarily on
blood pressure, heart rate, the ECG, repolarization (APD),
the hERG (IKr) ion channel, and cardiac conduction.
An additional consideration to drug effects on heart
rhythm involves cardiac (ventricular) contractility. This has
largely been neglected by safety scientists and has only
recently become of potential interest in the cardiovascular
safety milieu (34). Contractility, it is thought could initially
represent a complementary readout to the current
cardiovascular endpoints assessed under the core-battery
ICH S7A guidance, but this could change. Several papers
have recently been published that evaluate direct measures of
contractility (in vivo), and contractility variables include left
ventricular pressure (LVP) and rate of contraction and
relaxation (±dP/dtmax) recorded directly via invasive cathe-
ter implantation (34,35).
Regardless of the constituents, the resultant data, in
addition to data acquired from acute and/or chronic toxicol-
ogy studies, are recommended to be analyzed using an
integrated risk assessment (IRA) (36). The IRA is a holistic
evaluation of non-clinical study results and is used because
there has been no conclusion regarding which single non-
clinical model could be used to accurately address issues
highlighted by the regulatory guidance documents. However,
the value ascribed to data derived from in vitro and in vivo
studies is limited by other factors which may distort the
perceived safety of a drug (37,38). These factors include
differences in the pharmacokinetic and pharmacodynamic
relationship between animals and humans as well as differ-
ences between species regarding metabolism and plasma
protein binding as well as variability in species dependence
of TdP susceptibility (39). Despite such differences, the assays
currently used in non-clinical safety studies can be used to
inform the planning of clinical trials. Note that the informa-
tion acquired during the conduct of human trials will always
surpass that of the non-clinical studies in terms of relevance.
Conduct of a clinical development program, prior to
approval application, provides a rigorous assessment of the
drug’s propensity to prolong the QT interval in humans.
Thorough QT studies (TQT) involve quantification of the
degree of the drug’s influence on cardiac repolarization in
healthy volunteers as compared to placebo and a positive
control (moxifloxacin). The aim of the TQTstudies is to identify
drugs that clinically require more attention toward the potential
for development of a cardiac liability and therefore require
additional ECGmonitoring in subsequent clinical trials to assess
arrhythmia risk in the target patient population. Although the
TQT studies are informative and the best amongst the currently
available methods, they may not be cost-effective and suffer
from a low positive predictive value (40).
The classical approach to the assessment of proarrhythmia
occurs via the so called thorough QT (TQT) study that looks for
the largest excursion following a dose (a guard against
hysteresis) and checks whether the upper confidence limit
excludes the effect size deemed of potential clinical relevance.
Using the ICH E14 guidance, the upper 90% confidence limit
and a boundary of 10 ms defines the risk. However, hysteresis is
rarely observed in practice, so this procedure is both inefficient
in the use of available data to look for an effect and is biased
toward incompletely compensating for multiplicity by taking the
largest observed value amongst several time points.
Exposure-response modeling offers advantages in effi-
ciency by combining what is known across all time points and
several doses. It is also relatively simple because there is
usually a linear relationship between exposure and QT for
the small effects that are of interest. Indeed, such assessments
have long been performed as supplements to the classical
analyses of TQT studies. However, as supplementary analy-
ses, these have not had full prespecification and are thus
regarded as exploratory.
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Recent work has taken a more systematic approach, with
full prespecification of analytic methods, including tests for
linearity. Retrospective application of formal methods of
exposure-response analysis across selected studies was found
to be encouraging, but Food and Drug Administration (FDA)
insisted on a prospective study, too, and named a small set of
drugs and doses with peak effects in the neighborhood of
10 ms to be assessed (41)
The conducted study was a three-period, third-party
blinded, randomized, placebo-controlled study in 20 healthy
volunteers. The design was planned to be similar to a single
ascending dose (SAD) phase 1 study with the primary
objective to estimate the effect of the drugs on the QTc
interval using ER analysis. Each subject undergo three
treatment periods. An incomplete block design was used
what resulted in each study drug being administered to nine
subjects and placebo to six subjects in separate periods. The
design, sample size, and statistical approach is intended to
result in similar power to exclude clinically relevant QTc
effects as a standard SAD FIM study (41).
Exposure-response methods have now been established
in order to provide a more efficient assessment of the QT
interval, making such an assessment potentially a part of early
phase clinical studies where the highest doses are likely to be
utilized, and obviating conduct of a dedicated, expensive
TQT study. However, this methodology still makes use of a
biomarker whose correlation to proarrhythmic risk is not
absolute.
To address the deeper problem, we can potentially make
use of fundamental understanding of the mechanism by which
torsade-like arrhythmias are generated, and the ability to assess
in vitro drug effects on the machinery derived from humans.
Torsade occurrence requires two things. The first is a
relative failure of the cardiac myocyte to execute the
repolarization phase of the action potential. Following the
upstroke and plateau phases, the myocyte should re-establish
polarity, allowing the trigger to be reset for the next action
potential at its expected time. During this time, the repolar-
ization forces, in the form of outward currents, must be
vigorous enough to suppress any residual tendency for
regenerative activity. Thus, inadequate outward current
activity during this time allows inward, depolarizing current
to get the upper hand leading to “early afterdepolarizations”
(EADs), essentially, new action potentials happening long
before they are due.
As long as these EADs happen more or less throughout
the myocardium in synchrony, they are generally harmless. At
least, following one bad beat, things are likely to settle back
to normal activity (42,43). This is why patients with intrinsic
or drug-induced problems with repolarization can live de-
cades without a fatal arrhythmia. So, the second criterion for
setting up an arrhythmia is some degree of heterogeneity in
the heart. If all parts of the heart are not working in
synchrony, say, because of regional ischemic disease, scarring
due to an healed infarct, etc., the errant action potential has
some place to conduct and then is able to back-propagate and
re-excite cardiac tissue into what becomes a circuitous activity
(42). During such an event, the usual muscular coordination is
lost and the pumping action of the heart is interrupted. Such
effect has been widely studied and discussed from various
perspectives (44).
Although we can find evidence for the electrical
uncoupling in the heart and can model its effects to gain
insights into proarrhythmic mechanisms, fully characterizing a
patient’s intrinsic risk in this regard lies outside what is
technically feasible today. Judging when an arrhythmia will
occur and in whom is not possible. Judging which drugs are
likely to create the conditions that give rise to EADs is, on
the other hand, quite feasible (see above). Cardiac myocytes
have multiple ion channel types (see Fig. 1), and the human
channels of each type can be studied in isolation in cells
overexpressing single types. Each channel type can have the
effect of a drug assessed in vitro under voltage clamp
conditions, and high-throughput systems permit replicate
experiments, exposure-response characterization, etc. to be
performed at modest cost. If you know the channel densities
in human cardiac myocytes, you can then reconstruct the
human cardiac myocyte action potential, as it is influenced by
time-varying drug exposure, in silico, and look for the
propensity to produce EADs. That is, at the level of the
individual human cardiac ventricular myocyte, the process of
developing an action potential is completely understood, and
drug effects can be completely characterized.
Because this technology assesses drug effects across all,
or most, of the set of cardiac ion channel types, it should have
the ability to detect drugs with isolated adverse effects on
repolarization and to differentiate those drugs from the ones
with mixed effects on depolarizing and repolarizing forces,
resulting in less net risk.
In practice, there are some uncertainties. For example,
you cannot be sure that the voltage clamp protocol you used
will always capture the effect of a drug on the ion channel,
Fig. 1. A cardiac action potential that outlines the major currents
involved in depolarization and repolarization of the cell membrane.
The cardiac action potential (AP) conventionally consists of several
phases (0–4) with a duration of ∼300 ms. Phase 0 corresponds to
membrane depolarization (Na+ influx thru INa channels) while phase
1 shows the early rapid repolarization of the membrane due to
activation of the transient outward (Ito) K current. Phase 2 is the
plateau of the AP (due to a reduction in Na+ influx) and an increase
in Ca2+ influx (thru ICa channels) while phase 3 shows membrane
repolarization resulting from the coordinated opening and closing of
many different K+ channels such as the rapid (IKr) and slow (IKs)
components of the delayed rectifier K channel. Phase 4 corresponds
to the resting membrane potential and is maintained by the inward
rectifier (IK1) channel. The effects of a drug that produces a
prolongation in the AP by blockade of IKr is shown (drug (circle))
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because that effect may depend on some aspect of the
channel’s history that your protocol did not account for.
There can also be effects of drugs that are not the result of
direct interaction with the channel protein. It is, therefore, of
interest to augment such a channel-based assay with some
information from a more integrated (and thus less easily
characterized) system. Two such candidates are being
explored.
Ventricular myocytes can be obtained directly from
adult human ventricles, but sufficient availability cannot
yet be guaranteed by vendor sources (45). Human
embryonic or pluripotent stem cells can be induced to
form ventricular myocytes, which can be cultured in vast
numbers, and these are available from numerous commer-
cial sources. While they do not currently replicate the
electrophysiological phenotype of myocytes from the adult
human heart, they can be used, once correctly engineered,
to provide some assessment of drug effects that might be
missed by the use of the hERG channel-based assay
alone.
Another approach to attaining supplementary informa-
tion on drug effects is to return to the human ECG. The
upstroke of the action potential is reflected in the QRS
interval of the ECG, and repolarization is represented by the
QT interval. Drugs with a variety of known channel effects
have predictable effects on the morphology of the ECG
waveform, and understanding these relationships and what is
meant by their changes can help make predictions about
underlying channel effects (with potential clinical implica-
tions) of novel drugs.
In Vitro–In Vivo Extrapolation of a Drugs’ Proarrhythmic
Effect—From High-Throughput to Rare Case Analysis
All the abovementioned methods focus on a single
compound or at most in combination with metabolites
when an in vivo system is in use, and idealistic (or non-
realistic) conditions which are not complimentary with the
real life situation where the drug of interest is used. Even
a cursory analysis of the literature-reported TdP cases
suspected to be drug-triggered depicts one element which
seems to be overlooked, namely the influence of external
factors.
Multiple elements can be listed as external factors, and
the list below does not cover all possible components:
1. Concomitant drugs and the pharmacokinetic (PK) and
pharmacodynamics (PD) drug–drug interactions
2. Food and other environmental factors
3. Demographic and physiological parameters and their
drug-triggered modification
4. Genetic factors and comorbidity
Apart from a direct influence on the drug affinity to the
channels, all of the above-listed elements can modify drug
pharmacokinetics. It has been widely proven that the
variability of physiological parameters directly modify drug
pharmacokinetics and exposure (46–48). Therefore, cardiac
risk should ideally be assessed at the level of the individual
patient and also account for non-drug-related parameters
potentially triggering serious health-threatening situations.
Examples of such situations can be highlighted amongst the
drugs which are currently on the market or were withdrawn
due to non-acceptable cardiac risk. To support such a
statement, a brief, non-exhaustive analysis and description
of the commonly known proarrhythmic drugs has been
performed and discussed to draw attention to the role of
these non-drug parameters.
Cisapride is often given as an exemplary non-cardiology
drug associated with the risk of TdP (49). Cisapride, a
serotonin 5-HT4 receptor agonist, was developed in 1980 as
a prokinetic agent that increased gastrointestinal motility. It
has also been used for the treatment of gastroesophageal
reflux disease. In vitro studies revealed that it was a potent IKr
current inhibitor with in vitro measured IC50 values in the
range of 4.3–100 nM depending on the study settings (50).
However, it has other ion channel properties that include late
calcium (ICaL) current inhibition with IC50 values in the
micromolar range (51). According to all known classification
schemes including those developed by Redfern, Mirams, and
Crediblemeds (https://www.crediblemeds.org/), it is a drug
associated with a high propensity for proarrhythmic risk
(9,52,53). This assignment of risk is based on case reports of
side effect including TdP and other types of arrhythmias,
especially when the medication was taken concomitantly with
other medications or in patients with certain underlying
conditions predisposing them to arrhythmias. Wysowski
et al. analyzed the post-marketing reports of QT prolongation
and ventricular arrhythmia associated with cisapride (54).
From 1993 until 1999, while being marketed in the USA, the
FDA received 341 individual patient reports of multiple
heart-related conditions including 117 associated with QT
prolongation, 107 with TdP, 16 with polymorphic ventricular
tachycardia, and 27 with ventricular tachycardia. Eighty
(23%) of the 341 patients died. The authors concluded that
in most cases, an arrhythmia occurred in the presence of
additional, complex risk factors including the presence of
other drugs and/or variant medical conditions. Among other
strictly contraindicated factors that were listed include
concomitant use of CYP3A4 enzyme inhibitors, serious heart
conditions, electrolyte disorders, and overdose. A similar
situation was reported in the case study provided by Hussain
and Ghazal (55). These authors report the medical situation
of a 36-year-old woman presented to the emergency room
after 3 days of abdominal pain, fever, nausea, and vomiting
preceded by a Caesarean section. She was treated by multiple
drugs including antiarrhythmic drugs and cisapride which
were considered as the reasons for the developed ventricular
tachycardia which degenerated to frequent episodes of TdP.
After testing multiple factors, the authors concluded that the
observed TdP might not be solely due to drug-induced QT
interval prolongation. Other factors discussed by the attend-
ing clinicians include those caused by hypokalemia resulting
from repeated vomiting and poor nutritional intake and
metabolic drug–drug interactions which altered cisapride
exposure. Cisapride was withdrawn from many global mar-
kets in 2000 but remains available for use in some EU
countries to specific patients under strict black-box restric-
tions. Use by these specific patients requires that both health
care providers and patients receiving cisapride are familiar
with this complication associated with use and that all parties
understand and comply with specific recommendations
outlined and required for use.
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Trimebutine, a drug used to regulate motility in the
gastrointestinal tract via an agonist effect on peripheral μ-, κ-,
and δ- opiate receptors and modulation of gastrointestinal
and extragastric peptide release (i.e., motilin, vasoactive
intestinal peptide, gastrin, and glucagon), is provided as an
example distinctly different from that of cisapride.
Trimebutine is a weak inhibitor of IKr currents in guinea pig
ventricular myocytes as described by Morisawa and col-
leagues, with negligible effects, even at concentrations much
higher than those in clinical use (56). As may be expected,
based on such studies, trimebutine is classified as a drug
without known TdP risk (53). Surprisingly, a Eudravigilance
system (i.e., a data processing network and management
system for reporting and evaluating suspected adverse drug
reactions) query resulted in the finding of two records that
involve cases of TdP associated with its use (57). Both cases
were reported by health care professionals which increases
their potential credibility, but interestingly, both cases con-
cern effects on elderly patients (65–85 years of age). Such
reports do not provide a complete set of information and
obviously cannot be used as strong evidence of potential risk
but can be used in signal generation. Additionally, a quick
literature search (scholar.google.com) found one report
where significant QT interval prolongation and monomorphic
ventricular tachycardia was observed with high doses of
trimebutine (58). Monomorphic ventricular tachycardia, as
opposed to the polymorphic variant, is less dangerous and
more easily manageable but can degenerate to a polymorphic
form including TdP. The authors conclude that while there
may be a causal association between the occurrence of
arrhythmia and the use of high doses of trimebutine, it is
only probable. However, this may be sufficient to warrant
further review to quantify drug and non-drug-related trigger-
ing factors (in this case—sex, age, and plasma electrolytes).
In most cases, the clinically observed effect is likely the
consequence of the multiple actions the drug impart on
varying physiological systems. For some drugs, metabolites
contain inhibitory activity against ionic currents; therefore,
knowledge about their pharmacokinetics and pharmacody-
namics allows for a better prediction of the cardiac effects and
clinical data interpretation. In 2010, after 13 years of a
presence on market, the US FDA issued a safety announce-
ment regarding Anzemet (dolasetron mesylate—an antiemet-
ic 5-HT3 receptor inhibitor) use, informing patients and
health professionals that the injectable form of Anzemet
should no longer be used to prevent nausea and vomiting
associated with cancer chemotherapy (CINV) in pediatric and
adult patients (59,60). Such a decision was undertaken after
review of dolasetron-induced TdP cases (61). The drug can
still be used in postoperative nausea and vomiting prophy-
laxis and treatment because lower doses are used for these
indications. Dolasetron is rapidly metabolized to a reduced
form of hydrodolasetron (MDL 74,156) by carbonyl reduc-
tase, an enzyme widely distributed in human tissues (62,63).
In view of this manner of metabolism, dolasetron is consid-
ered as a prodrug that is converted to hydrodolasetron, which
is believed to be responsible for the majority of clinical
activity (64,65). Additionally 5′-OH and 6′-OH metabolite
derivatives are considered as carrying partial activity. When
given orally, dolasetron plasma concentration is in most cases
undetectable and its pharmacological activity is negligible,
although after intravenous injection both active moieties are
present at the site of action and trigger potential cardiac
effects. Orally taken, dolasetron formulations are still in use
for all indications and considered as safe (66). There was
however a case study published where a massive orally taken
dolasetron dose (2000 mg, p.o.) was taken. The patient’s
ECG showed first-degree heart block along with non-specific
intraventricular conduction delay and a prolonged QTc
interval (67).
The above given example indicates that the route-
dependent kinetic actions of drugs should be considered
during drug safety analysis and that a combination of the
active substances (i.e., parent and metabolites) rather than a
single entity (i.e., the parent molecule) should be studied for
safety purposes. This is done depending upon the levels of the
metabolites in the plasma (>10%) and whether they can be
synthesized and tested alone. Similarly, toxicology species are
assessed for parent and metabolite PK parameters to ensure
that adequate exposure of parent and metabolites occurs
during long-term toxicity assessments. There are multiple
examples of drug–drug interactions at the pharmacokinetic
and pharmacodynamic level which trigger potential toxic
effects with terfenadine and ketoconazole being probably the
most well-known examples (68). Consequences of the latter
are relatively easy to predict as ketoconazole-driven CYP3A4
inhibition and subsequent blockade of terfenadine metabo-
lism resulted in substantial increases in terfenadine blood
concentrations in combination with potent inhibition of the
IKr current resulted in QT interval prolongation and precip-
itation of TdP arrhythmias. At the daily routine level, what is
probably most important to assess is the non-linear effect of
the drug combination. Such a situation was described for
droperidol and ondansetron where, despite of lack of
exposure modification after concomitant dosing, the QT
interval was prolonged, but the observed prolongation was
not proportional to the QT prolongation observed for two
drugs given separately (69).
Considering the complexity of the above-listed phenome-
na, their thorough analysis during the conduct of clinical trials
would be very challenging, if not impossible. What’s more,
clinical trial characteristics, namely a relatively small cohort,
homogeneity of the included individuals, short period of drug
exposure, rare drug–drug and drug–environment interaction
analysis, could contribute to relatively poor prediction of rare
cases observed in subsequent clinical studies. The solutionmight
be the development of a relatively tight safety margin for the
analyzed TdP risk surrogate as was proposed in the ICH E14
guideline. There is however a cost connected with that as it
might, and probably has, provoked genesis of a high percentage
of false positives and thus a high clinical attrition rate of many
drug candidates (1). As was mentioned above, this was one of
the reasons for the inception of a new cardiac safety testing
paradigm discussion and likely introduction. An inevitable
component of this new paradigm is in silico methods which
should became a vital element of cardiac safety testing. These
include various approaches, starting from screening methods
(QSAR-based models), up to the utilization of the biophysically
detailed cardiac myocyte models (15,70). The latter techniques
vary with regard of the level of complexity of the mathematical
description of the cardiac physiology at the ion channel
(Hodgkin-Huxley or Markovian notation) and cell level (single
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cell up to the three-dimensional heart structure) (71,72). Such
methods offer the possibility to incorporate variability of either
stochastic or deterministic nature (73,74). This can further allow
for the drug cardiac safety analysis at the population level and
quantitative assessment of the combination of drug and non-
drug-related parameters (36,75,76).
Some elements should include the need for proper exposure
quantification. The effect at the clinical level is related to the
concentrations of the tested substances. However, plasma drug
concentration (which is the most common effective concentration
surrogate) can be imperfect as it may vary from that in the tissues.
Therefore, more suitable effector concentration methods should
be considered whenever available, possibly in the places where
drug might meet cardiac ion channels (i.e., pericardial fluid, heart
cell extracellular matrix, and cardiomyocyte cytoplasm).
Something that is impossible in clinical practice can be potentially
incorporated via the application of a physiologically based
pharmacokinetic (PBPK) modeling and simulation approach.
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